Literature DB >> 8756382

Trilateral retinoblastoma. A report of five patients.

W M Amoaku1, H E Willshaw, S E Parkes, K J Shah, J R Mann.   

Abstract

BACKGROUND: Trilateral retinoblastoma is a well recognized, although rare, syndrome. Most of the reported cases have involved a family history of retinoblastoma (RB) and the disease is almost always fatal. The authors chose to investigate the cases of trilateral retinoblastoma occurring in the West Midlands, a region of the United Kingdom with an increasing incidence of bilateral sporadic RB.
METHODS: Five patients with trilateral retinoblastoma (including two were previously reported), diagnosed in 146 consecutive patients with RB in the West Midlands Health Authority Region between 1957 and 1994, are presented (an incidence of 3%). Their clinical presentation, treatment, and outcome are described.
RESULTS: There were 4 patients with pineoblastoma, only one of whom had a positive family history. The mean age at diagnosis of RB and 6 months, whereas the patients with pineoblastoma were diagnosed at a mean age of 2 years 8 months. The tumors were not evident on the initial computed tomography scans. One child presented with a calcified suprasellar mass 13 months before the bilateral sporadic RB was identified. Death occurred within 1 month of diagnosis of the intracranial tumor in 3 patients who did not receive any treatment. In the other 2 patients who were treated, death occurred at 15 months and 2 years 7 months, respectively, after diagnosis of intracranial tumor.
CONCLUSIONS: Early diagnosis with regular neuro-imaging and more aggressive treatment may improve prognosis in patients with RB and an intracranial tumor.

Entities:  

Mesh:

Year:  1996        PMID: 8756382     DOI: 10.1002/(SICI)1097-0142(19960815)78:4<858::AID-CNCR24>3.0.CO;2-T

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  High-dose chemotherapy followed by autologous and allogeneic peripheral blood stem cell transplantation for recurrent disseminated trilateral retinoblastoma.

Authors:  Toshihisa Tsuruta; Yasuo Aihara; Hitoshi Kanno; Chikako Kiyotani; Katsuya Maebayashi; Masako Sakauchi; Makiko Osawa; Hisaichi Fujii; Osami Kubo; Yoshikazu Okada
Journal:  Childs Nerv Syst       Date:  2011-03-19       Impact factor: 1.475

2.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

3.  Successful treatment of early detected trilateral retinoblastoma using standard infant brain tumor therapy.

Authors:  Karen D Wright; Ibrahim Qaddoumi; Zoltan Patay; Amar Gajjar; Matthew W Wilson; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

4.  A Potential Role For Apparent Diffusion Coefficient in the Diagnosis of Trilateral Retinoblastoma.

Authors:  Sameer Farouk Sait; Sofia Haque; Sasan Karimi; Karim J Rebeiz; Jasmine H Francis; Brian P Marr; David H Abramson; Mark M Souweidane; Ira J Dunkel
Journal:  J Pediatr Hematol Oncol       Date:  2020-04       Impact factor: 1.289

Review 5.  Trilateral retinoblastoma: an institutional experience and review of the literature.

Authors:  Elzbieta Jurkiewicz; Iwona Pakuła-Kościesza; Olga Rutynowska; Katarzyna Nowak
Journal:  Childs Nerv Syst       Date:  2009-07-31       Impact factor: 1.475

6.  The RB1 gene mutation in a child with ectopic intracranial retinoblastoma.

Authors:  Z Onadim; A J Woolford; J E Kingston; J L Hungerford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  CRX is a diagnostic marker of retinal and pineal lineage tumors.

Authors:  Sandro Santagata; Cecile L Maire; Ahmed Idbaih; Lars Geffers; Mick Correll; Kristina Holton; John Quackenbush; Keith L Ligon
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.